Meanwhile, targeted drugs (such as HER2 or VEGF monoclonal antibodies) and immunotherapy (such as PD-1 or PD-L1 blockade) are emerging as first-line treatments for advanced GC [31,103] . The gene discussed is ERBB2; the disease is gastric cancer.